Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
about
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeProof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaImpact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.How we manage autologous stem cell transplantation for patients with multiple myelomaTotal Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyChromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapiesCuring myeloma at last: defining criteria and providing the evidence.Complete response after autologous stem cell transplant in multiple myelomaMultiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapyImprovement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.IMWG consensus on risk stratification in multiple myeloma.Response evaluation and monitoring of multiple myeloma.Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.Risk Stratification in Multiple Myeloma.Management of high-risk Myeloma: an evidence-based review of treatment strategies.Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145.Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response.Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group.Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group.Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
P2860
Q26782868-9E407C0C-7EFB-4EBF-8A46-71BE7443C752Q28537857-1907D100-A6A2-4F04-957F-019E92915365Q30301228-8B2B3460-6A8C-4174-B219-F6F93657451CQ33887470-446A3C81-6D8A-4D68-9962-314A74888368Q33990944-73F75833-B119-4D1B-9FB0-EE8D609C03A0Q34019581-A0615017-516C-44D9-9279-3C95B859A5D0Q34122646-86DA32EC-9BBD-4CC2-B262-0491B0CB273EQ34272540-22EEB619-7E6B-4446-9CE8-F834127CA616Q34508313-33160015-89D4-49D6-BC3E-7BCCF0069A07Q35000475-411F30F3-83E5-474B-8A92-378E68530E75Q35061518-9B690371-7F51-40ED-A2CA-C888F2A77979Q37096649-25186D69-3C33-4E99-8E9A-7E09AF060A70Q37348247-AFF1FF39-F984-49FC-B849-70E11E3DC7ADQ37411236-F16B8291-0A21-4560-85FA-FE7215129391Q37761370-4AEFF344-61D5-4891-B9D7-AAAFC039F155Q37835695-A3E04D3E-62B4-4D21-947B-BF9F3206BFE6Q37946246-909F7202-6564-4ED5-B9E3-27B340E1B5A9Q38131380-06CBD86F-155E-4EAF-9819-67AEA76EE63FQ38183872-6F9F4877-8736-4F17-879E-8023AE2F9021Q38249930-D1D9415D-4D46-47BF-9F13-9BE43DB35D70Q38375463-937C5398-5AB1-4764-A777-5377AA2B53E7Q38394274-CF241F3C-A366-4241-A2D1-A693F1CF9D74Q38417073-38D3F6F1-46CC-49EA-98C1-A2515049C662Q38662385-6EA45F7C-5A93-48C5-94CD-A2A043822455Q38736249-1B66CDD8-60B9-4C9C-A0F9-DED8A73BCCE0Q38874675-DFB623EF-3CFC-40D0-A839-1793195EDCE7Q41525599-AACB86A8-8DDC-42FA-8FCC-74D845913CB1Q42924712-78C37071-1EFE-44D2-A543-98342038F390Q46427111-78DAF682-278B-4755-9BB8-49D376DDBD2FQ48102038-186768FA-6EB0-4136-927C-BFF5316E3D75Q48338656-01C52E86-7781-4B94-9310-2D6A6CA263B0Q48848774-2DF01F77-E4A1-4C9C-BE5E-21FBA3E7C4D2Q49641900-A0C92EFC-BCFF-4289-9727-6B2CFC09CF8FQ53095991-B1DBE548-C7AB-434E-9026-976CC3EF0304Q53130957-679F81B8-4A06-41E8-A4BC-60934B0B35D9Q53148481-BA2944BA-4124-49C6-9035-6A132D3B84E2
P2860
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Complete remission in multiple ...... on in Total Therapy protocols.
@en
Complete remission in multiple ...... on in Total Therapy protocols.
@nl
type
label
Complete remission in multiple ...... on in Total Therapy protocols.
@en
Complete remission in multiple ...... on in Total Therapy protocols.
@nl
prefLabel
Complete remission in multiple ...... on in Total Therapy protocols.
@en
Complete remission in multiple ...... on in Total Therapy protocols.
@nl
P2093
P2860
P50
P1433
P1476
Complete remission in multiple ...... on in Total Therapy protocols.
@en
P2093
Bijay Nair
Jackie Szymonifka
John Crowley
John D Shaughnessy
Klaus Hollmig
Yazan Alsayed
P2860
P304
P356
10.1182/BLOOD-2009-03-211953
P407
P577
2009-06-10T00:00:00Z